Activity Provided By:

The University of Texas MD Anderson Cancer Center

Therapeutic Advancements for the Treatment of High-Risk MDS: Future Opportunities to Improve Patient Survival and Quality of Life

Overview / Abstract:	Are you up to date on MDS? Engage with a leading oncology expert on recent changes in MDS classification and risk assessment of risk. Learn about emerging therapies for high-risk MDS and how they may impact clinical practice through case discussions. Do you have questions about the latest in MDS, such as: - What are the classifications of MDS? - What is the IPSS-M, and how do I use it to assess risk? - How should I manage patients with high-risk MDS? - What are the unmet needs for patients with high-risk MDS? - Are there emerging therapies for high-risk MDS, and how do they work? - Where might emerging therapies fit in the current treatment paradigm? Join the discussion to get answers to these questions and more! Don’t get left behind and be ready to incorporate emerging therapies into your treatment plans for high-risk MDS.
Expiration	Oct 17, 2023
Discipline(s)	Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME
Format	Live / Seminar
Credits / Hours	1.0
Accreditation	ACCME, AAPA, ANCC
Presenters / Authors / Faculty	Daniel Pollyea, MD, MS Professor of Medicine Clinical Director of Leukemia Services Associate Chief of Clinical Affairs Robert H. Allen MD Chair in Hematology Research Division of Hematology University of Colorado School of Medicine Aurora, CO
Sponsors / Supporters / Grant Providers	Provided by The University of Texas MD Anderson Cancer Center and the Academy for Continued Healthcare Learning (ACHL). The organizing committee wishes to express appreciation to the following company for their commitment to continuing medical education by providing an educational grant in support of this educational activity: Gilead Sciences, Inc.
Keywords / Search Terms	ACHL Pollyea, DiNardo, hematology, pathology, oncology, transfusion, MDS, myelodysplastic syndromes, high-risk MDS, HR-MDS, CD47, immune surveillance, mechanism of action, MOA, cytopenia, hemoglobin, dysplasia, cytogenetic testing, cytogenetics, karyotype, multidisciplinary, biopsy, neutropenia, myeloid neoplasm, hematopoiesis, bone marrow, hypercellularity, mutational testing, NGS, next generation sequencing, hypomethylating agent Free CE CME Seminar CE CME
LIVE Activity Location Details	Date(s) 10-17-2023 Online United States of America

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map